Compensatory activation of Akt in response to mTOR and Raf inhibitors - A rationale for dual-targeted therapy approaches in neuroendocrine tumor disease

Cancer Letters

Volumn 295, Issue 1, 2010, Pages 100-109

  Zitzmann, Kathrin ^a   Rüden, Janina von ^a   Brand, Stephan ^a   Göke, Burkhard ^a   Lichtl, Jennifer ^a   Spöttl, Gerald ^a   Auernhammer, Christoph J ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Apoptosis; G0 G1 arrest; Neuroendocrine tumors; PI(3)K Akt mTOR signaling; Ras Raf MEK Erk1 2 signaling; Small molecule inhibitor

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; CHIR 265; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAF PROTEIN; RAS PROTEIN; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG POTENCY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEEDBACK SYSTEM; HUMAN; HUMAN CELL; INHIBITION KINETICS; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROTEIN SECRETION; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEEDBACK, PHYSIOLOGICAL; G1 PHASE; HUMANS; IMIDAZOLES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MAP KINASE SIGNALING SYSTEM; NEUROENDOCRINE TUMORS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; PYRROLES; QUINOLINES; RAF KINASES; SIGNAL TRANSDUCTION; SIROLIMUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77953609118     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.02.018     Document Type: Article

References (36)

1. Kaltsas G.A., Besser G.M., Grossman A.B. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr. Rev. 2004, 25:458-511.
2. Mignon M. Natural history of neuroendocrine enteropancreatic tumors. Digestion 2000, 62(Suppl. 1):51-58.
3. Grant S. Cotargeting survival signaling pathways in cancer. J. Clin. Invest. 2008, 118:3003-3006.
4. Steelman L.S., Abrams S.L., Whelan J., Bertrand F.E., Ludwig D.E., Basecke J., Libra M., Stivala F., Milella M., Tafuri A., Lunghi P., Bonati A., Martelli A.M., McCubrey J.A. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia 2008, 22:686-707.
5. O'Reilly K.E., Rojo F., She Q.B., Solit D., Mills G.B., Smith D., Lane H., Hofmann F., Hicklin D.J., Ludwig D.L., Baselga J., Rosen N. MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006, 66:1500-1508.
6. Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307:1098-1101.
7. Hresko R.C., Mueckler M. mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J. Biol. Chem. 2005, 280:40406-40416.
8. Carracedo A., Pandolfi P.P. The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene 2008, 27:5527-5541.
9. Carracedo A., Ma L., Teruya-Feldstein J., Rojo F., Salmena L., Alimonti A., Egia A., Sasaki A.T., Thomas G., Kozma S.C., Papa A., Nardella C., Cantley L.C., Baselga J., Pandolfi P.P. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest. 2008, 118:3065-3074.
10. Shah T., Hochhauser D., Frow R., Quaglia A., Dhillon A.P., Caplin M.E. Epidermal growth factor receptor expression and activation in neuroendocrine tumours. J. Neuroendocrinol. 2006, 18:355-360.
11. von Wichert G., Jehle P.M., Hoeflich A., Koschnick S., Dralle H., Wolf E., Wiedenmann B., Boehm B.O., Adler G., Seufferlein T. Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Res. 2000, 60:4573-4581.
12. Zitzmann K., Vlotides G., Göke B., Auernhammer C.J. PI(3)K-Akt-mTOR pathway as a potential therapeutic target in neuroendocrine tumors. Exp. Rev. Endocrinol. Metabol. 2008, 3:207-222.
13. Zitzmann K., De Toni E.N., Brand S., Goke B., Meinecke J., Spottl G., Meyer H.H., Auernhammer C.J. The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology 2007, 85:54-60.
14. Grozinsky-Glasberg S., Franchi G., Teng M., Leontiou C.A., Ribeiro de Oliveira A., Dalino P., Salahuddin N., Korbonits M., Grossman A.B. Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell line. Neuroendocrinology 2008, 87:168-181.
15. Yao J.C., Phan A.T., Chang D.Z., Wolff R.A., Hess K., Gupta S., Jacobs C., Mares J.E., Landgraf A.N., Rashid A., Meric-Bernstam F. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J. Clin. Oncol. 2008, 26:4311-4318.
16. Karhoff D., Sauer S., Schrader J., Arnold R., Fendrich V., Bartsch D.K., Horsch D. Rap1/B-Raf signaling is activated in neuroendocrine tumors of the digestive tract and Raf kinase inhibition constitutes a putative therapeutic target. Neuroendocrinology 2007, 85:45-53.
17. Hobday T.J., Rubin J., Holen K., Picus J., Donehower R., Marschke R., Maples W., Lloyd R., Mahoney M., Erlichman C. MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): a Phase II Consortium (P2C) study. J. Clin. Oncol. 2007, 25.
18. Zitzmann K., Brand S., Baehs S., Goke B., Meinecke J., Spottl G., Meyer H., Auernhammer C.J. Novel interferon-lambdas induce antiproliferative effects in neuroendocrine tumor cells. Biochem. Biophys. Res. Commun. 2006, 344:1334-1341.
19. Nicoletti I., Migliorati G., Pagliacci M.C., Grignani F., Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods. 1991, 139:271-279.
20. Weinstein I.B., Joe A. Oncogene addiction. Cancer Res. 2008, 68:3077-3080. (discussion 3080).
21. Serra V., Markman B., Scaltriti M., Eichhorn P.J., Valero V., Guzman M., Botero M.L., Llonch E., Atzori F., Di Cosimo S., Maira M., Garcia-Echeverria C., Parra J.L., Arribas J., Baselga J. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res. 2008, 68:8022-8030.
22. Huang S., Robinson J.B., Deguzman A., Bucana C.D., Fidler I.J. Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res. 2000, 60:5334-5339.
23. Lim J.H., Lee E.S., You H.J., Lee J.W., Park J.W., Chun Y.S. Ras-dependent induction of HIF-1alpha785 via the Raf/MEK/ERK pathway: a novel mechanism of Ras-mediated tumor promotion. Oncogene 2004, 23:9427-9431.
24. Mizukami Y., Kohgo Y., Chung D.C. Hypoxia inducible factor-1 independent pathways in tumor angiogenesis. Clin. Cancer Res. 2007, 13:5670-5674.
25. Skinner H.D., Zheng J.Z., Fang J., Agani F., Jiang B.H. Vascular endothelial growth factor transcriptional activation is mediated by hypoxia-inducible factor 1alpha, HDM2, and p70S6K1 in response to phosphatidylinositol 3-kinase/AKT signaling. J. Biol. Chem. 2004, 279:45643-45651.
26. Sabatini D.M. MTOR and cancer: insights into a complex relationship. Nat. Rev. Cancer 2006, 6:729-734.
27. Ma L., Chen Z., Erdjument-Bromage H., Tempst P., Pandolfi P.P. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 2005, 121:179-193.
28. Meng F., Dong B., Li H., Fan D., Ding J. RNAi-mediated inhibition of Raf-1 leads to decreased angiogenesis and tumor growth in gastric cancer. Cancer Biol. Ther. 2009, 8.
29. Galabova-Kovacs G., Matzen D., Piazzolla D., Meissl K., Plyushch T., Chen A.P., Silva A., Baccarini M. Essential role of B-Raf in ERK activation during extraembryonic development. Proc. Natl. Acad. Sci. USA 2006, 103:1325-1330.
30. Stuart, K. Aardalen, E. Venetsanakos, T. Nagel, M. Wallroth, D. Batt, S. Ramurthy, D. Poon, M. Faure, E. Lorenzana, F. Salangsang, J. Dove, E. Garrett, M. Aikawa, A. Kaplan, P. Amiri, P. Renhowe, RAF265 is a Potent Raf Kinase Inhibitor with Selective Anti-proliferative Activity in vitro and in vivo. AACR Meeting Abstracts Online 2008.
31. Motzer R.J., Michaelson M.D., Redman B.G., Hudes G.R., Wilding G., Figlin R.A., Ginsberg M.S., Kim S.T., Baum C.M., DePrimo S.E., Li J.Z., Bello C.L., Theuer C.P., George D.J., Rini B.I. Activity of SU11248. A multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2006, 24:16-24.
32. Ebos J.M., Lee C.R., Christensen J.G., Mutsaers A.J., Kerbel R.S. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc. Natl. Acad. Sci. USA 2007, 104:17069-17074.
33. Kerbel R.S. Tumor angiogenesis. New Engl. J. Med. 2008, 358:2039-2049.
34. Bocci G., Man S., Green S.K., Francia G., Ebos J.M., du Manoir J.M., Weinerman A., Emmenegger U., Ma L., Thorpe P., Davidoff A., Huber J., Hicklin D.J., Kerbel R.S. Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies. Cancer Res. 2004, 64:6616-6625.
35. Stacchiotti S., Tamborini E., Marrari A., Brich S., Rota S.A., Orsenigo M., Crippa F., Morosi C., Gronchi A., Pierotti M.A., Casali P.G., Pilotti S. Response to sunitinib malate in advanced alveolar soft part sarcoma. Clin. Cancer Res. 2009, 15:1096-1104.
36. Buck E., Eyzaguirre A., Rosenfeld-Franklin M., Thomson S., Mulvihill M., Barr S., Brown E., O'Connor M., Yao Y., Pachter J., Miglarese M., Epstein D., Iwata K.K., Haley J.D., Gibson N.W., Ji Q.S. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res. 2008, 68:8322-8332.